<DOC>
	<DOCNO>NCT02490709</DOCNO>
	<brief_summary>The purpose study evaluation safety efficacy transanal local excision patient cT3 rectal cancer downstaged ycT0-1 neoadjuvant chemoradiotherapy .</brief_summary>
	<brief_title>Local Excision Clinical T3 Rectal Adenocarcinoma Showing Major Response ( ycT0-1 ) After Neoadjuvant Chemoradiotherapy</brief_title>
	<detailed_description>This study prospective multicenter single-arm phase II clinical trial . Rectal cancer patient cT3 stage receive neoadjuvant chemoradiotherapy , evaluate response tumor 6 10 week completion neoadjuvant chemoradiotherapy . For good response ( ycT0-1 ) underwent transanal local excision patient ' agree .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<criteria>age : 20 year biopsyproven adenocarcinoma rectum clinical staging , cT3NxM0 Rectal cancer locate 8 cm anal verge Restaging 610 week completion neoadjuvant chemoradiotherapy , ycT01N0M0 ECOG performance status 2 less Synchronous colon cancer malignancy Obstructing rectal cancer Pregnant breastfeed Receiving study agent History prior colorectal cancer inflammatory bowel disease Hereditary colorectal cancer ( FAP , HNPCC )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Rectal neoplasm</keyword>
	<keyword>Colorectal neoplasm</keyword>
	<keyword>Local excision</keyword>
</DOC>